A Phase 3 interventional study of Nicotinamide and Placebo in Non-melanoma Skin Cancer, Carcinoma, Squamous Cell and Carcinoma, Basal Cell, sponsored by Women's College Hospital. Recruiting at 7 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Women's College Hospital · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Carcinoma, Squamous Cell with a site in Canada — 5 open to participants now, 9 under way, 4 of them phase 3. Carcinoma, Squamous Cell · Canada.
Among the 45 studies in Carcinoma, Squamous Cell with a site in Canada, this one is the 11th largest by planned enrollment of the 42 interventional ones that give a count, is the only one that started in 2023, is one of 12 in phase 3, and was the 41st registered.
629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.
Browse Carcinoma, Squamous Cell studies →5 of the 45 studies in Carcinoma, Squamous Cell with a site in Canada are open now. Recruiting first, the newest first:
AVEO Pharmaceuticals, Inc. · Sites in Canada, United States, Australia and 15 more countries
Ages 18+
Johnson & Johnson Enterprise Innovation Inc. · Sites in Canada, United States, Austria and 24 more countries
Ages 60+
Bicara Therapeutics · Sites in Canada, United States, Australia
Ages 18+
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada, Australia
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 16 · Phase 3 14 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 396 is above the median of 45 across 478 interventional studies indexed under Carcinoma, Squamous Cell.
Median enrollment 112 across the 42 interventional studies, 18 across the 3 observational. Of the 31 that completed or were terminated, 12 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 45 have an industry lead sponsor. The 10 most frequent:
Women's College Hospital is the lead sponsor of 87 studies on the registry; 16 are open to participants now.
Women's College Hospital has 2 studies filed under Carcinoma, Squamous Cell — fewer than ten, so there is no comparison to draw.
5 of the studies in Carcinoma, Squamous Cell with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05955924Phase 3Women's College HospitalNicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial | 2027-08 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT06578871London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sSurgery and Reducing Ionizing Radiation of the Unknown Primary | 2026-12-31 |
| NCT05323253Alpha Tau Medical LTD.Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma | 2027-04 |
| NCT04429542Bicara TherapeuticsStudy of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 45 studies in Carcinoma, Squamous Cell with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection. In particular, long-term use of these drugs increases the risk of skin cancer. Skin cancer is now a leading cause of illness and disfigurement after kidney, liver, heart, and lung transplantation. Given the increased risk and burden of skin cancer in transplant recipients, prevention is critical.
Nicotinamide is a form of Vitamin B3 that has been shown to protect against skin cancer in the general population. However, it is unclear whether nicotinamide is effective among immune-suppressed transplant recipients. Investigators will conduct a clinical trial involving multiple transplant centres in Canada to evaluate whether oral nicotinamide (500 mg twice daily) is effective and safe for preventing skin cancer. Investigators will recruit 396 high-risk adult kidney, liver, heart, and lung transplant patients who have previously had at least one skin cancer. Patients will receive nicotinamide or sham tablets for up to 4 years. The results will inform efforts to improve the long-term health of transplant recipients.
Improved survival after solid organ transplantation has created the need to better prevent the long-term adverse effects of immunosuppressant drugs in transplant survivors - particularly cancer development. Keratinocyte carcinoma (non-melanoma skin cancer) is by far the most common form of post-transplant malignancy and has a more aggressive clinical course than in the general population. Preventive measures are thus critical to reduce the burden of skin cancer in the high-risk transplant population.
Nicotinamide is a low-cost, commercially available, over-the-counter Vitamin B3 derivative that has been found to safely reduce the rate of keratinocyte carcinoma in immunocompetent patients with a history of skin cancer. It is unclear whether its efficacy and safety translate to the immunosuppressed transplant population.
Given this uncertainty, Investigators plan to build on our internal pilot study (N=120) to conduct the SPRINTR (Skin cancer PRevention with Nicotinamide in Transplant Recipients) pivotal trial to address these specific aims:
Primary question: Does oral nicotinamide (500 mg twice daily) reduce the rate of further keratinocyte carcinoma compared with placebo when used in addition to standard care for up to 208 weeks in high-risk solid organ transplant recipients?
Secondary questions:
Investigators will conduct a multicentre, pragmatic, parallel group, investigator- and patient-blinded, randomized trial with a superiority framework. This pivotal trial will evaluate the efficacy and safety of oral nicotinamide versus placebo to prevent further keratinocyte carcinoma in 396 high-risk solid organ transplant recipients. Data from our previous internal pilot study (N=120 participants) will be combined with data from the current pivotal trial (N=276 additional patients) in the final analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention Drug : Nicotinamide
Drug: Nicotinamide
Intervention: Placebo Oral Capsule
Drug: Placebo
Oral nicotinamide (500 mg) twice daily
Also known as: niacinamide
Matching placebo capsule twice daily
Time to first biopsy-confirmed keratinocyte carcinoma (basal cell carcinoma or invasive cutaneous squamous cell carcinoma)
Time frame: Up to 208 weeks
Time to first invasive squamous cell carcinoma during follow-up
Time frame: Up to 208 weeks
Time to first basal cell carcinoma during follow-up
Time frame: Up to 208 weeks
Time to multiple keratinocyte carcinomas over follow-up
Time frame: Up to 208 weeks
Occurrence of adverse events during follow-up
Overall and by body system, frequency, seriousness, and severity
Time frame: 208 weeks
Acute graft rejection (biopsy-confirmed)
Adverse event
Time frame: 208 weeks
Graft loss or retransplantation
Adverse event
Time frame: 208 weeks
High/low cyclosporine or tacrolimus blood concentration requiring dose adjustment
Adverse event
Time frame: 208 weeks
Change from baseline in annual Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) score
Time frame: 52 weeks
Change from baseline in annual Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) score
Time frame: 104 weeks
Change from baseline in annual Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) score
Time frame: 156 weeks
Change from baseline in annual Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) score
Time frame: 208 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)
Time frame: 52 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)
Time frame: 104 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)
Time frame: 156 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Montreal Cognitive Assessment (MoCA)
Time frame: 208 weeks
Neurocognitive substudy - Proportion of participants with cognitive impairment
As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)
Time frame: 52 weeks
Neurocognitive substudy - Proportion of participants with cognitive impairment
As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)
Time frame: 104 weeks
Neurocognitive substudy - Proportion of participants with cognitive impairment
As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)
Time frame: 156 weeks
Neurocognitive substudy - Proportion of participants with cognitive impairment
As defined by the International Cognition and Cancer Task Force (T scores ≥2 standard deviations below the normative population mean on a single test, or ≥1.5 standard deviations below the mean on at least two tests, or both)
Time frame: 208 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised
Time frame: 52 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised
Time frame: 104 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised
Time frame: 156 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Hopkins Verbal Learning Test - Revised
Time frame: 208 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B
Time frame: 52 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B
Time frame: 104 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B
Time frame: 156 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Trail Making A and B
Time frame: 208 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association
Time frame: 52 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association
Time frame: 104 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association
Time frame: 156 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Controlled Oral Word Association
Time frame: 208 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task
Time frame: 52 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task
Time frame: 104 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task
Time frame: 156 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Animal Naming Task
Time frame: 208 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).
Time frame: 52 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).
Time frame: 104 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).
Time frame: 156 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Wechsler Adult Intelligence Scale-Fourth Edition-Canadian (WAIS-IV-CDN).
Time frame: 208 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest
Time frame: 52 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest
Time frame: 104 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest
Time frame: 156 weeks
Neurocognitive substudy - Change from baseline in demographically-corrected T score for Digit Span subtest
Time frame: 208 weeks
Plan to share: Yes — The trial protocol and statistical code will be shared upon request. Beyond 18 months after trial completion, the anonymized participant-level dataset will made available for sharing with external researchers upon approval of a reasonable study proposal describing the intended data usage.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Beyond 18 months after trial completion.
Access criteria: Data will be made available for sharing with external researchers upon approval of a well-defined study proposal that clearly outlines the intended use of the data.
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Aug 2027, 48 months after the start.
Of 21 phase 3 interventional studies under Carcinoma, Squamous Cell, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 91. This study's planned 48 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niacinamide
Women's College Hospital